2022
PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBD
Sayed A, Silveira M, Assis D, Deng Y, Gaidos J, Proctor D, Al-Bawardy B. PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBD. Inflammatory Bowel Diseases 2022, 28: s76-s76. DOI: 10.1093/ibd/izac015.124.Peer-Reviewed Original ResearchPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDSmall bowel involvementClinical remissionEndoscopic healingIMM groupAutoimmune hepatitisBowel involvementUrsodeoxycholic acidExact testBackground Inflammatory bowel diseaseEpisodes of cholangitisRate of cholangitisThird of patientsUnpaired Student's t-testFisher's exact testT-testSmall molecule therapiesStudent's t-testThiopurine monotherapyImmunosuppressive therapySclerosing cholangitisAdult patientsBiologic therapy
2008
Utilization of and Adherence to the Gastroenterology Core Curriculum on Hepatology Training During a Gastrointestinal Fellowship
Guardino JM, Proctor DD, Lopez R, Carey W. Utilization of and Adherence to the Gastroenterology Core Curriculum on Hepatology Training During a Gastrointestinal Fellowship. Clinical Gastroenterology And Hepatology 2008, 6: 682-688.e2. PMID: 18356116, DOI: 10.1016/j.cgh.2007.12.038.Peer-Reviewed Original ResearchConceptsProgram director assessmentsDiagnosis/managementFisher's exact testProgram directorsImmunosuppressant useClinical trainingFulminant diseaseLiver biopsyPatient selectionTransplant institutionsPregnancy issuesExact testTraining programAbstractTextFellowship trainingCongenital disorderLack of trainingDirectors' assessmentsKnowledge/skillsAIMSHepatology trainingAdherenceFuture studiesQuestionnaireAdequate time